# Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers

> **NCT05847218** · PHASE1 · COMPLETED · sponsor: **RH Nanopharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Safety
- Tolerability
- Pharmacokinetics

## Interventions

- **DRUG:** RHN-001 (one tablet 750mg)
- **DRUG:** RHN-001 (750mg * 2 Tablets)

## Key facts

- **NCT ID:** NCT05847218
- **Lead sponsor:** RH Nanopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-09
- **Primary completion:** 2023-03-19
- **Final completion:** 2023-03-19
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05847218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05847218, "Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05847218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*